Literature DB >> 18222004

CZE-ICP-MS as a tool for studying the hydrolysis of ruthenium anticancer drug candidates and their reactivity towards the DNA model compound dGMP.

Michael Groessl1, Christian G Hartinger, Paul J Dyson, Bernhard K Keppler.   

Abstract

Elucidating the mode of action and thereby opening the way to the design of chemotherapeutic agents is one of the major goals of metal-based anticancer research. Hydrolysis and DNA binding play an important role for pharmaceutical formulation and for exerting anticancer activity. Herein, for the first time the application of capillary zone electrophoresis-inductively-coupled plasma mass spectrometry (CZE-ICP-MS) for studying the hydrolytic stability and the binding of the ruthenium anticancer drug candidates KP418, KP1019, and RAPTA-C to dGMP is described. RAPTA-C was found to hydrolyze fastest and showed the highest reactivity toward the DNA model compound, whereas KP418 was the most stable compound in both these respects.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18222004     DOI: 10.1016/j.jinorgbio.2007.11.018

Source DB:  PubMed          Journal:  J Inorg Biochem        ISSN: 0162-0134            Impact factor:   4.155


  12 in total

1.  Cobalt complexes as internal standards for capillary zone electrophoresis-mass spectrometry studies in biological inorganic chemistry.

Authors:  Hannah U Holtkamp; Stuart J Morrow; Mario Kubanik; Christian G Hartinger
Journal:  J Biol Inorg Chem       Date:  2017-01-02       Impact factor: 3.358

2.  Metabolization of [Ru(eta(6)-C (6)H (5)CF (3))(pta)Cl (2)]: a cytotoxic RAPTA-type complex with a strongly electron withdrawing arene ligand.

Authors:  Alexander E Egger; Christian G Hartinger; Anna K Renfrew; Paul J Dyson
Journal:  J Biol Inorg Chem       Date:  2010-04-06       Impact factor: 3.358

3.  Ruthenium versus platinum: interactions of anticancer metallodrugs with duplex oligonucleotides characterised by electrospray ionisation mass spectrometry.

Authors:  Michael Groessl; Yury O Tsybin; Christian G Hartinger; Bernhard K Keppler; Paul J Dyson
Journal:  J Biol Inorg Chem       Date:  2010-03-07       Impact factor: 3.358

4.  Polymeric Micelle-Mediated Delivery of DNA-Targeting Organometallic Complexes for Resistant Ovarian Cancer Treatment.

Authors:  Xiaopin Duan; Demin Liu; Christina Chan; Wenbin Lin
Journal:  Small       Date:  2015-05-12       Impact factor: 13.281

5.  The first example of MEEKC-ICP-MS coupling and its application for the analysis of anticancer platinum complexes.

Authors:  Anna K Bytzek; Michael R Reithofer; Markus Galanski; Michael Groessl; Bernhard K Keppler; Christian G Hartinger
Journal:  Electrophoresis       Date:  2010-04       Impact factor: 3.595

6.  Reactions of Ru(III)-drugs KP1019 and KP418 with guanine, 2'-deoxyguanosine and guanosine: a DFT study.

Authors:  Pramod Kumar Shah; Nihar R Jena; Pradeep Kumar Shukla
Journal:  J Mol Model       Date:  2022-09-05       Impact factor: 2.172

7.  Electronic structural investigations of ruthenium compounds and anticancer prodrugs.

Authors:  Travis V Harris; Robert K Szilagyi; Karen L McFarlane Holman
Journal:  J Biol Inorg Chem       Date:  2009-04-07       Impact factor: 3.358

8.  Serum-protein interactions with anticancer Ru(III) complexes KP1019 and KP418 characterized by EPR.

Authors:  Naniye Cetinbas; Michael I Webb; Joshua A Dubland; Charles J Walsby
Journal:  J Biol Inorg Chem       Date:  2009-08-26       Impact factor: 3.358

9.  X-ray absorption near edge structure spectroscopy to resolve the in vivo chemistry of the redox-active indazolium trans-[Tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019).

Authors:  Alfred A Hummer; Petra Heffeter; Walter Berger; Martin Filipits; David Batchelor; Gabriel E Büchel; Michael A Jakupec; Bernhard K Keppler; Annette Rompel
Journal:  J Med Chem       Date:  2013-01-31       Impact factor: 7.446

10.  Altered DNA binding and amplification of human breast cancer suppressor gene BRCA1 induced by a novel antitumor compound, [Ru(η(6)-p-phenylethacrynate)Cl(2)(pta)].

Authors:  Korawan Chakree; Chitchamai Ovatlarnporn; Paul J Dyson; Adisorn Ratanaphan
Journal:  Int J Mol Sci       Date:  2012-10-15       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.